Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells

Biomedicine and Pharmacotherapy

Volumn 63, Issue 3, 2009, Pages 202-208

  Sun, Li rui ^a   Li, Xun ^a   Cheng, Yan na ^a   Yuan, Hong yu ^a   Chen, Ming hui ^a   Tang, Wei ^b   Ward, Stephen Geoffrey ^c   Qu, Xian jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b University of Tokyo   (Japan)

^c University of Bath   (United Kingdom)

Author keywords

K562 A02 cells; Multidrug resistance (MDR); P glycoprotein (P gp); Reversal effect; Substituted 1,3 dimethyl 1H quinoxalin 2 ones

Indexed keywords

1,3 DIMETHYL 1H QUINOXALIN 2 ONE; DOXORUBICIN; GLYCOPROTEIN P; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CANCER INHIBITION; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; EXCITATION; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; INHIBITION KINETICS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCENT DYES; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOID; P-GLYCOPROTEIN; QUINOXALINES; RHODAMINE 123;

EID: 61349086677     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.07.090     Document Type: Article

References (27)

1. Avendano C., and Menendez J.C. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9 (2002) 159-193
2. Robert J. Approaches to multidrug resistance reversal. Expert Opin Investig Drugs 7 (1998) 929-939
3. Aszalos A., Ladanyi A., Bocsi J., and Szende B. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. Cancer Lett 167 (2001) 157-162
4. Lopes E.C., Garcia M., Benavides F., Shen J., Conti C.J., Alvarez E., et al. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Leuk Res 27 (2003) 413-423
5. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 324 (2008) 95-102
6. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61 (2001) 749-758
7. Lawrence D.S., Copper J.E., and Smith C.D. Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J Med Chem 44 (2001) 594-601
8. Li X., Wang D., Wu J., and Xu W. Synthesis of substituted 1,3-dimethyl-1H-quinoxalin-2-ones from aniline derivatives. Heterocycles 65 (2005) 2741-2751
9. Qi J., Liu N., Zhou Y., Tan Y., Cheng Y., Yang C., et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 349 (2006) 303-309
10. Ji B.S., and He L. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. J Pharm Pharmacol 59 (2007) 1011-1015
11. Pu Y.S., Hsieh M.W., Wang C.W., Liu G.Y., Huang C.Y., Lin C.C., et al. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 71 (2006) 751-760
12. Zhu B., Liu G.T., Zhao Y.M., Wu R.S., and Strada S.J. Chemosensitizing multiple drug resistance of human carcinoma by bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. Cancer Biol Ther 5 (2006) 536-543
13. Ji B.S., He L., and Liu G.Q. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci 77 (2005) 2221-2232
14. Sachs-Barable K., Thamboo A., Lee S.D., and Wasan K.M. Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within caco-2 cells. J Pharm Pharm Sci 10 (2007) 319-331
15. Limtrakul P., Khantamat O., and Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17 (2005) 86-95
16. Kim S.Y., Kim D.H., Han S.J., Hyun J.W., and Kim H.S. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells. Biochem Pharmacol 74 (2007) 1642-1651
17. Okutucu B., Dincer A., Habib O., and Zihnioqlu F. Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 70 (2007) 709-711
18. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65 (2005) 516-525
19. Lee B.D., Li Z., French K.J., French K.J., Zhuang Y., Xia Z., et al. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem 47 (2004) 1413-1422
20. Lee B.D., French K.J., Zhuang Y., and Smith C.D. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res 14 (2003) 49-60
21. Thomas G.A., Barrand M.A., Stewart S., Rabbitts P.H., Williams E.D., and Twentyman P.R. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridization. Eur J Cancer 30A (1994) 1705-1709
22. Abbaszadegan M.R., Futscher B.W., Klimecki W.T., List A., and Dalton W.S. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54 (1994) 4676-4679
23. Di Pietro A., Conseil G., Perez-Victoria J.M., Dayan G., Baubichon-Cortay H., Trompier D., et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59 (2002) 307-322
24. Varma M.V., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48 (2003) 347-349
25. Lehnert M., de Giuli R., and Twentyman P.R. Sensitive and rapid bioassay for analysis of P-glycoprotein-inhibiting activity of chemosensitizers in patient serum. Clin Cancer Res 2 (1996) 403-410
26. Vanhuyse M., Kluza J., Tardy C., Otero G., Cuevas C., Bailly C., et al. A novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett 221 (2005) 165-175
27. Green L.J., Marder P., and Slapak C.A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 6 (2001) 1393-1399